Clinical Trial

Intradermal, Fractional Dose of HPV Vaccines:

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-01-16; most recent amendment 2026-04-28.
Status change: Not Yet Recruiting → Active, Not Recruiting 2022-03-04
Trial Details
NCT Number NCT04235257
Lead Sponsor University of Washington
Conditions HPV Infection, HPV Vaccine
Enrollment 40 participants
Start Date 2020-11-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05